Uri Herzberg

Uri Herzberg currently serves as Chief Drug Discovery Officer at Evozyne since September 2023. Prior to this position, Uri was VP and Head of Translational Research at Fresh Tracks Therapeutics and held various leadership roles at Cabaletta Bio, Celularity, Inc., Celgene, Johnson & Johnson, Neurogen Corporation, Acorda Therapeutics, Cytotherapeutics, and the NIH. Expertise includes inflammation, pain, immune disorders, and neuroscience, with significant involvement in drug discovery and translational research. Academic credentials include a DVM from Washington State University, an MBA in Pharmaceutical Development from Fairleigh Dickinson University, and a PhD in Veterinary Biology and Neuroimmunology from the University of Minnesota.